trending Market Intelligence /marketintelligence/en/news-insights/trending/jsyBIaGtP8J59kvVL0Oy9g2 content esgSubNav
In This List

Peregrine Pharmaceuticals names president/CEO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Peregrine Pharmaceuticals names president/CEO

Peregrine Pharmaceuticals Inc. appointed Roger Lias as its president and CEO, succeeding Steven King, who resigned to pursue other professional interests.

Lias is currently a member of Peregrine's board and also serves as the president of Avid Bioservices, a subsidiary of the company. He has more than 20 years of contract development and manufacturing organization, or CDMO, management experience

"We believe that Roger is best equipped to lead Peregrine, including the completion of the company's transition to a pure play CDMO operating under the Avid Bioservices name. With the demand for biologics manufacturing exceeding the industry's current capacity and expected to continue to grow in coming years, Roger and his team have worked aggressively to establish a strategic plan that we anticipate will allow the company to take advantage of this significant market opportunity," Peregrine Chairman Joseph Carleone said in a statement.